As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

Being a long-term investor isn't always easy, as you'll inevitably encounter downturns as well as the thriving bull periods that occur in a cyclical market. However, this is a far better alternative ...

Here, six house and techno artists provide a look into what it’s like being a tastemaker spinning at Time Warp. They discuss their favorite memories, why the event is special to them and more.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

ThinkCell CIO Tony Bell explores how market-driven strategies and price signals shape effective investment decisions.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.